Methadone is a Food and Drug Administration- (FDA-) approved medication for treating opioid use disorder (OUD), a chronic brain disease that affects more than 2.7 million people in the United States aged 12 and older. Despite its effectiveness in saving lives, many barriers impede access to, initiation of, and retention in methadone treatment for OUD. To address these barriers, on March 3 and 4, 2022, the National Academies of Sciences, Engineering, and Medicine hosted a workshop on "Methadone Treatment for Opioid Use Disorder: Examining Federal Regulations and Laws," at the request of the Office of National Drug Control Policy in the Executive Office of the President. This publication summarizes the presentation and discussion of the workshop.
National Academies of Sciences, Engineering, and Medicine. 2022. Methadone Treatment for Opioid Use Disorder: Improving Access Through Regulatory and Legal Change: Proceedings of a Workshop. Washington, DC: The National Academies Press. https://doi.org/10.17226/26635.
|1 Introduction and Background||1-6|
|2 Methadone Treatment: Personal Perspectives||7-12|
|3 The History of Methadone and Barriers to Access for Different Populations||13-28|
|4 Current Federal Priorities and Regulatory Flexibilities during the COVID-19 Pandemic||29-44|
|5 Improving Access to Quality Treatment in Opioid Treatment Programs through Regulatory Innovation||45-58|
|6 Improving Access to Quality Treatment in the Criminal Justice System and Other Institutional Settings||59-72|
|7 Expanding Access to Methadone through Regulatory Innovation: Envisioning Approaches Outside the Opioid Treatment Program System||73-88|
|8 Ensuring Equitable Access to Methadone by Removing Current Barriers and Providing Incentives||89-96|
|9 Frameworks to Guide the Assessment of Legal and Regulatory Challenges||97-104|
|10 Moving Forward: Potential Concrete Legal and Regulatory Actions||105-116|
|Appendix A: References||117-124|
|Appendix B: Workshop Agenda||125-134|
|Appendix C: Commissioned Papers||135-168|
The Chapter Skim search tool presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter. You may select key terms to highlight them within pages of each chapter.
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, pleaseclick here to view more information.